SillaJen and Lee’s Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in ChinaPhase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

Seoul, Korea, San Francisco, Ca., Hong Kong, China —Sept. 4, 2018 — SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and Lee’s Pharmaceutical Holdings Ltd., announced the first patient has been enrolled in China in the Phase 3 PHOCUS clinical trial of the oncolytic immunotherapy Pexa-Vec (formerly JX-594) for advanced liver cancer.

ดาวน์โหลดข่าวฉบับเต็ม (PDF)

ที่มา: Lee’s Pharmaceutical Holdings – News & Media